Barclays PLC Decreases Stock Holdings in Solventum Corporation $SOLV

Barclays PLC reduced its stake in shares of Solventum Corporation (NYSE:SOLV) by 16.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 339,587 shares of the company’s stock after selling 67,814 shares during the period. Barclays PLC owned 0.20% of Solventum worth $24,790,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. JT Stratford LLC grew its holdings in Solventum by 5.9% in the 3rd quarter. JT Stratford LLC now owns 27,489 shares of the company’s stock valued at $2,007,000 after buying an additional 1,536 shares in the last quarter. Skba Capital Management LLC raised its holdings in shares of Solventum by 26.2% during the 3rd quarter. Skba Capital Management LLC now owns 9,290 shares of the company’s stock worth $678,000 after acquiring an additional 1,930 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Solventum by 3.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 544,285 shares of the company’s stock valued at $39,728,000 after acquiring an additional 18,516 shares during the last quarter. Cresset Asset Management LLC boosted its position in shares of Solventum by 16.8% during the 3rd quarter. Cresset Asset Management LLC now owns 8,496 shares of the company’s stock valued at $620,000 after acquiring an additional 1,223 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Solventum by 11.9% in the third quarter. Victory Capital Management Inc. now owns 126,245 shares of the company’s stock valued at $9,216,000 after purchasing an additional 13,384 shares during the period.

Solventum Stock Up 0.0%

Solventum stock opened at $67.62 on Thursday. The firm has a market capitalization of $11.73 billion, a P/E ratio of 7.62, a P/E/G ratio of 1.11 and a beta of 0.40. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $88.20. The stock’s fifty day simple moving average is $76.91 and its 200-day simple moving average is $76.08.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.96 billion. During the same period last year, the firm earned $1.41 earnings per share. Solventum’s quarterly revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its board has approved a stock repurchase program on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 7.5% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. KeyCorp raised their price objective on shares of Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. UBS Group reissued a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Wells Fargo & Company reduced their price target on shares of Solventum from $86.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $100.00 price objective on shares of Solventum in a report on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Solventum has a consensus rating of “Moderate Buy” and a consensus target price of $93.70.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.